Gliprip-M3 Plus Tablet PR is a combination oral antidiabetic medication containing Glimepiride 3mg and Metformin 850mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, enhances pancreatic beta-cell insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to reduced blood glucose levels. The prolonged-release formulation ensures a sustained therapeutic effect, promoting better patient compliance through once-daily dosing. Gliprip-M3 Plus is indicated for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve optimal glycemic targets. It is essential to monitor blood glucose regularly to adjust dosage and avoid hypoglycemia, a potential adverse effect due to increased insulin secretion. Caution is advised in patients with renal impairment, hepatic dysfunction, or cardiovascular disease. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, typically associated with metformin. This combination therapy should be used as part of a comprehensive diabetes management plan, including lifestyle modifications. Gliprip-M3 Plus Tablet PR offers an effective option for improving glycemic control in type 2 diabetes patients requiring combination oral hypoglycemic therapy.